Tysabri Long-Term Users Must Provide Additional Consent In Europe
A three-month EMEA safety review confirms that two years of treatment with the monoclonal antibody increases the risk for PML.
A three-month EMEA safety review confirms that two years of treatment with the monoclonal antibody increases the risk for PML.